Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 113.44M P/E - EPS this Y -3,000.00% Ern Qtrly Grth -
Income 11.09M Forward P/E -1.86 EPS next Y -96.80% 50D Avg Chg -
Sales 119.57M PEG 4.30 EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book N/A EPS next 5Y -0.90% 52W High Chg -43.00%
Recommedations 2.10 Quick Ratio 0.98 Shares Outstanding 78.12M 52W Low Chg 46.00%
Insider Own 1.00% ROA 1.94% Shares Float 66.34M Beta 1.04
Inst Own 72.26% ROE - Shares Shorted/Prior 6.98M/7.87M Price 1.71
Gross Margin 100.00% Profit Margin 9.27% Avg. Volume 379,900 Target Price 5.31
Oper. Margin -33.65% Earnings Date Nov 5 Volume 196,695 Change 1.18%
About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CytomX Therapeutics, Inc. News
11/21/24 JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
11/20/24 Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
11/19/24 Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
11/19/24 CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
11/09/24 CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/08/24 Q3 2024 CytomX Therapeutics Inc Earnings Call
11/08/24 CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
11/07/24 CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates
11/07/24 CytomX Therapeutics: Q3 Earnings Snapshot
11/07/24 CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
10/31/24 CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
09/09/24 CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
09/04/24 CytomX Therapeutics to Present at Upcoming September Investor Conferences
08/10/24 CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
08/08/24 CytomX Therapeutics: Q2 Earnings Snapshot
08/08/24 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08/01/24 CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
07/25/24 CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?
07/22/24 CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company
06/18/24 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CTMX Chatroom

User Image rickahuna Posted - 1 day ago

$CTMX "Helping people retain a quality of life during cancer treatment" That's what the masking and conditional activation do. While the drug is more effective at the cancer site, it also less toxic to normal tissue. Many patients want to live a semi normal life while fighting their cancer; QOL is important because depression can make any treatment less efficacious.

User Image rickahuna Posted - 1 day ago

$CTMX Paid and presented by CytomX Therapeutics. "The biology of cancer cells can make them hard to target without damaging other cells in the process. Uncover how immunotherapy treatments are continually evolving, and what "masking" and "conditional activation" have to do with more effectively targeting tumours." <------ British audience spelling ...Interesting advertisement! Thank you for posting.

User Image AKnee Posted - 1 day ago

$CTMX patience Danielson https://www.bbc.com/storyworks/rewriting-cancer/the-science-behind-targeting-tumours

User Image Gator5326 Posted - 2 days ago

$CTMX what is going on with this stock? 🤦‍♂️

User Image Pukkaa56 Posted - 4 days ago

$CTMX

User Image KaGi77 Posted - 4 days ago

$CTMX I'm not selling until at least the end of 2025. Too many pipeline projects in the works that I want to see play out for a while. Scared money don't make no money.

User Image bb5019 Posted - 4 days ago

$CTMX were screwed

User Image NVDAMillionaire Posted - 4 days ago

$CTMX CytomX Therapeutics (CTMX): Pioneering Innovative Therapeutics in Oncology https://beyondspx.com/article/cytomx-therapeutics-inc-ctmx-a-promising-biotech-poised-for-growth

User Image Rheis Posted - 5 days ago

$CTMX can't believe I still have my average at 5.93, becoming tempting to average down

User Image KaGi77 Posted - 5 days ago

$CTMX This truly has no business being under $1. Ridiculous manipulation for months now IMO.

User Image 30Puffy Posted - 5 days ago

$CTMX

User Image Silver_Discgolfer Posted - 5 days ago

$CTMX Not selling, but WTF happened here?

User Image Andiko78 Posted - 5 days ago

$CTMX ok. From solid to shortable.

User Image Andiko78 Posted - 5 days ago

$CTMX

User Image Bulltrader988 Posted - 1 week ago

$CTMX tutes increased their ownerships in the last quarter. Tang is still in. https://fintel.io/so/us/ctmx

User Image GJ_Rockabilt Posted - 1 week ago

$CTMX

User Image GJ_Rockabilt Posted - 1 week ago

$CTMX Bold Red.

User Image rickahuna Posted - 1 week ago

$CTMX Don't limit your sights. Cytomx technology can be used for more than oncology. Remember in 2023-The collaboration will see Moderna hand over $35 million upfront—with up to $1.2 billion to potentially follow in milestones—to use CytomX Therapeutics’ Probody technology. The tech is designed to “enable proteins to be activated locally in diseased tissue, while remaining masked in systemic circulation.” In other words, it could help direct Moderna’s growing array of investigational mRNA therapies for both oncology and beyond to their desired target in the body. And Amgen has not given any signs of discontinuing AMG 651 (CX-904) is a T-cell engaging bispecific Probody® candidate against epidermal growth factor receptor (EGFR) and CD3. It is being investigated for the treatment of solid tumors. ADDITIONAL INFORMATION AMG 651 is being developed in collaboration with CytomX Therapeutics, Inc.

User Image LabPsycho Posted - 1 week ago

$CTMX Most biotechs continue to take a beating for over 2 yr now, plus the countless BioGrifters offering massive InstaDilutions(TM) on the way down for over 2 yr now has wiped many investors out and soured any kind of enthusiasm for Biotechs / (most are BioScams in my opinion). Considering that + my speculations below, I see this getting below 70 cents soon. The big debt also a concern. One might be tempted to go with 20K shares @ $0.49 and hope for a Jan bounce, provided it drifts down just because rather than on bad news. Good luck.

User Image BioMan122 Posted - 1 week ago

$CTMX what did i say? do you remember?

User Image AKnee Posted - 1 week ago

$CTMX anyone else now concerned that they will be kicked off NASDAQ for not maintaining $1 price?

User Image KaGi77 Posted - 1 week ago

$CTMX Looking like the RFK effect has hit all Bio stocks today. What a nightmare.

User Image Biotech2424 Posted - 1 week ago

Baby Keytruda at Coherus shorts going to burn 🔥 $CHRS $MRK $CTMX $MNPR

User Image KaGi77 Posted - 1 week ago

$CTMX Well, to that matter, Tang Capital opened a new 7.8 M position filed yesterday as well.

User Image Tz123 Posted - 1 week ago

$CTMX what’s the catalyst here?

User Image AKnee Posted - 1 week ago

$CTMX Cormorant just filed the same but it looks like they dumped all their shares according to the filing today

User Image AKnee Posted - 1 week ago

$CTMX filed today by Janus Henderson 4.8M shares New Form SC 13G/A for CytomX Therapeutics, Inc.

User Image SAVYGUY55 Posted - 1 week ago

$CTMX good PR coming soon

User Image HerrmannKraut Posted - 1 week ago

$CTMX There can only be one direction

User Image Bobby_J_Bomb Posted - 1 week ago

$XBI $VTGN $CTMX $SPRB $VSTM Some of the best opportunities in this beat to shit sector if FOMO trades come back hard. Took some major profits on VSTM in last 2 weeks, but still holding a few for the ride. The other 3 will have major late phase readouts and strong cash. This sector has been destroyed for almost 4 years, since Trump left office.

Analyst Ratings
HC Wainwright & Co. Neutral Sep 13, 24
HC Wainwright & Co. Neutral Aug 22, 24
HC Wainwright & Co. Neutral Jun 27, 24
Piper Sandler Overweight May 28, 24
BMO Capital Market Perform May 9, 24
HC Wainwright & Co. Neutral May 9, 24
Wedbush Outperform May 9, 24
Jefferies Buy May 6, 24
BMO Capital Market Perform May 1, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BELVIN MARCIA SVP, Chief Scientifi.. SVP, Chief Scientific Officer Sep 20 Sell 1.3 4,119 5,355 147,951 09/22/23
Landau Jeffrey B Chief Business Offic.. Chief Business Officer Sep 20 Sell 1.3 4,119 5,355 76,379 09/22/23
McCarthy Sean A. CEO CEO Sep 20 Sell 1.3 14,601 18,981 430,755 09/22/23
ROWLAND LLOYD A General Counsel General Counsel Sep 20 Sell 1.3 5,486 7,132 80,609 09/22/23
McCarthy Sean A. CEO CEO May 19 Option 1.5749 16,535 26,041 405,356 05/23/23
Jones Elaine V Director Director Mar 29 Buy 1.55 5,000 7,750 5,142 03/31/23
Ogden Christopher SVP, Finance and Acc.. SVP, Finance and Accounting Mar 16 Sell 1.9793 516 1,021 37,772 03/20/23
Campoy Carlos Chief Financial Offi.. Chief Financial Officer Mar 16 Sell 1.9791 1,748 3,459 38,224 03/20/23
McCarthy Sean A. CEO CEO Mar 16 Sell 1.8805 7,121 13,391 388,821 03/20/23
ROWLAND LLOYD A General Counsel General Counsel Mar 16 Sell 1.979 2,037 4,031 71,095 03/20/23
Landau Jeffrey B Chief Financial Offi.. Chief Financial Officer Mar 16 Sell 1.9792 1,477 2,923 69,248 03/20/23
Peterson Amy C. EVP, Chief Developme.. EVP, Chief Development Officer Mar 16 Sell 1.979 4,257 8,425 58,433 03/20/23
McCarthy Sean A. President and CEO President and CEO May 09 Option 0.95 90,931 86,384 265,853 05/11/22
McCarthy Sean A. President and CEO President and CEO Jun 16 Option 1.04 40 42 7,849 06/16/21
McCarthy Sean A. President and CEO President and CEO Apr 02 Option 1.13 100,000 113,000 306,894 04/02/21